[go: up one dir, main page]

WO2011133216A3 - Mutant nis protein and uses thereof - Google Patents

Mutant nis protein and uses thereof Download PDF

Info

Publication number
WO2011133216A3
WO2011133216A3 PCT/US2011/000703 US2011000703W WO2011133216A3 WO 2011133216 A3 WO2011133216 A3 WO 2011133216A3 US 2011000703 W US2011000703 W US 2011000703W WO 2011133216 A3 WO2011133216 A3 WO 2011133216A3
Authority
WO
WIPO (PCT)
Prior art keywords
nis
mutant
protein
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/000703
Other languages
French (fr)
Other versions
WO2011133216A2 (en
Inventor
Nancy Carrasco
Monika Belenitsky
Matthew J. Maestas
Sepehr Eskandari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Cal Poly Pomona Foundation Inc
Original Assignee
Albert Einstein College of Medicine
Cal Poly Pomona Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine, Cal Poly Pomona Foundation Inc filed Critical Albert Einstein College of Medicine
Publication of WO2011133216A2 publication Critical patent/WO2011133216A2/en
Publication of WO2011133216A3 publication Critical patent/WO2011133216A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are Na+/I- symporter (NIS) mutant proteins wherein glycine residue 93 is replaced with aspartic acid or glutamic acid, a method of preparing said mutant NIS protein, a transfection vector for a NIS mutant protein, and a pharmaceutical composition comprising said mutant NIS protein in a pharmaceutically acceptable carrier. The disclosure also provides a method of treating cancer or cancerous cells, comprising administering a therapeutically effective amount of a transfection vector for a NIS mutant protein or a pharmaceutical composition thereof, and administering a therapeutically effective amount of radioisotope. The disclosure further provides a method of imaging cells, comprising administering to the cells an effective amount of a transfection vector for a NIS mutant protein, administering a effective amount of imaging label, and imaging the cells.
PCT/US2011/000703 2010-04-22 2011-04-20 Mutant nis protein and uses thereof Ceased WO2011133216A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34298110P 2010-04-22 2010-04-22
US61/342,981 2010-04-22

Publications (2)

Publication Number Publication Date
WO2011133216A2 WO2011133216A2 (en) 2011-10-27
WO2011133216A3 true WO2011133216A3 (en) 2012-04-19

Family

ID=44834717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/000703 Ceased WO2011133216A2 (en) 2010-04-22 2011-04-20 Mutant nis protein and uses thereof

Country Status (1)

Country Link
WO (1) WO2011133216A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031137A2 (en) 2010-09-02 2012-03-08 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
WO2014197069A2 (en) * 2013-03-15 2014-12-11 Mayo Foundation For Medical Education And Research Radiotracer imaging using sodium iodide symporter polypeptides
WO2025257785A1 (en) 2024-06-14 2025-12-18 Istituti Clinici Scientifici Maugeri Spa Sb Compounds for use in the treatment and/or diagnosis of a pathology characterised by the expression of the na/i symporter (nis) in the affected cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000236A2 (en) * 2002-06-25 2003-12-31 The Ohio State University Research Foundation Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004000236A2 (en) * 2002-06-25 2003-12-31 The Ohio State University Research Foundation Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ESKANDARI: "Position 93 of the Na+/lodide Symporter (NIS) plays a critical role in Na+/Substrate Coupled Transport.", SCIENCE RESEARCH SYMPOSIUM 2010, 12 May 2010 (2010-05-12), Retrieved from the Internet <URL:http://www.csupomona.edu/-srs/absl0/Maestas.pdf> [retrieved on 20110913] *
HUC-BRANDT ET AL.: "Characterisation of the purified human sodium/iodide symporter reveals that the protein is mainly present in a dimeric form and permits the detailed study of a native C- terminal fragment.", BIOCHIM BIOPHYS ACTA, vol. 1808, no. 1, January 2011 (2011-01-01), pages 65 - 77 *
PARODER-BELENITSKY ET AL.: "Mechanism of anion selectivity and stoichiometry of the Na+/I- symporter (NIS).", PROC NATL ACAD SCI U S A., vol. 108, no. 44, 1 November 2011 (2011-11-01), pages 17933 - 8 *
REED-TSUR ET AL.: "Molecular Characterization of V59E NIS, a Na /I Symporter Mutant that Causes Congenital I Transport Defect.", ENDOCRINOLOGY., vol. 149, no. 6, 2008, pages 3077 - 84 *
VAN SANDE ET AL.: "Anion selectivity by the sodium iodide symporter.", ENDOCRINOLOGY, vol. 144, 2003, pages 247 - 252 *

Also Published As

Publication number Publication date
WO2011133216A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
TN2015000177A1 (en) Anti-ceacam5 antibodies and uses thereof
NZ601868A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2008057529A3 (en) Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
IN2014KN01713A (en)
IN2014KN01714A (en)
IN2014KN01716A (en)
MX353608B (en) Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same.
FI3778885T3 (en) COMPOSITIONS AND METHODS OF ENGINEERED HUMAN ARGINASES FOR TREATMENT OF CANCER
NZ612312A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
IN2012DN02981A (en)
MX2020011674A (en) Diagnosis and treatment of cancer based on avl9.
UA97516C2 (en) Fully human anti-vap-1 monoclonal antibody
NZ595825A (en) Antibody containing igg2 having amino acid mutation introduced therein
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
IN2014DN09963A (en)
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
WO2011133216A3 (en) Mutant nis protein and uses thereof
WO2011053065A3 (en) Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same
MX2007008980A (en) Nucleic acids for apoptosis of cancer cells.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772356

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11772356

Country of ref document: EP

Kind code of ref document: A2